Elicit: Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Clinical Outcomes of TNF Inhibition in RA and Psoriasis
Identify clinical evidence linking TNF inhibition to outcomes in rheumatoid arthritis and psoriasis
Abstract
TNF inhibitors demonstrate substantial therapeutic efficacy for psoriatic arthritis and psoriasis, with 37% of csDMARD-inadequate responders achieving clinical improvement (ACR50) versus 8% with placebo (RR 5.63, 95% CI 3.98 to 7.96). For moderate-to-severe plaque psoriasis, PASI 75 response rates reach 80-91% with infliximab compared to 3% with placebo, with therapeutic effects appearing within 4 weeks. However, paradoxical new-onset or worsening psoriasis emerges as a recognized adverse event in patients receiving TNF inhibitors for rheumatoid arthritis, occurring at 1.04 per 1000 person-years compared to 0 per 1000 person-years with traditional DMARDs. Adalimumab shows 4.6-fold higher incidence of paradoxical psoriasis than etanercept and 3.5-fold higher than infliximab, though no statistically significant differences in therapeutic effectiveness exist among anti-TNF agents. Most patients (66%) developing paradoxical psoriasis can continue TNF inhibitor therapy with concurrent psoriasis treatment, balancing control of the primary indication against induced skin disease.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Characteristics of Included Studies
The review included 10 studies published between 2000 and 2025, comprising 5 randomized controlled trials, 3 meta-analyses/systematic reviews, 1 prospective registry study, and 1 retrospective cohort study. These studies addressed TNF inhibition in three distinct contexts: therapeutic use for psoriatic arthritis, therapeutic use for psoriasis, and paradoxical psoriasis development during TNF inhibitor therapy for other conditions.
| Study | Full text retrieved? | Study Type | Target Condition | TNF Inhibitor(s) | Sample Size | Primary Outcomes |
|---|---|---|---|---|---|---|
| L. Lemos et al., 2014 | No | Systematic review and meta-analysis | Psoriatic arthritis | Adalimumab, etanercept, golimumab, infliximab | Not mentioned | ACR20, ACR50, PsARC, PASI75 |
| G. Cagnotto et al., 2025 | No | Systematic review and meta-analysis of RCTs | Psoriatic arthritis | TNFi (specific agents not mentioned) | 7857 | ACR50, HAQ, SF-36 MCS, Sharp/Van der Heijde-PsA |
| E. Shmidt et al., 2012 | No | Retrospective cohort study | Psoriasis as adverse event | Infliximab, adalimumab, etanercept | 56 | Complete or partial response |
| Mark Harrison et al., 2008 | Yes | Prospective observational cohort (registry) | Rheumatoid arthritis; psoriasis as adverse event | Etanercept, infliximab, adalimumab | 9826 anti-TNF, 2880 DMARD | Incidence of new-onset psoriasis |
| Angelique N. Collamer & D. Battafarano, 2010 | No | Systematic literature review | Psoriasis as adverse event in RA and other conditions | Infliximab, adalimumab, etanercept | 207 | Not mentioned |
| P. Mease et al., 2000 | No | Randomized controlled trial | Psoriatic arthritis and psoriasis | Etanercept 25 mg twice-weekly subcutaneous | 60 | PsARC, ACR20, PASI |
| N. Bansback et al., 2009 | No | Systematic review and meta-analysis | Psoriasis | Infliximab, adalimumab, etanercept | Not mentioned | PASI |
| U. Chaudhari et al., 2001 | No | Randomized controlled trial | Psoriasis | Infliximab 5 mg/kg and 10 mg/kg intravenous | 33 | Physician’s Global Assessment |
| K. Reich et al., 2005 | No | Randomized controlled trial | Psoriasis | Infliximab 5 mg/kg via infusion | 378 | PASI |
| K. Thorlund et al., 2012 | No | Indirect comparison meta-analysis | Psoriatic arthritis | Adalimumab, etanercept, golimumab, infliximab | Not mentioned | PsARC, HAQ, PASI |
Effects of TNF Inhibitors
Efficacy in Psoriatic Arthritis
TNF inhibitors demonstrated substantial clinical benefit in psoriatic arthritis across multiple outcome domains. In csDMARD-inadequate responders, TNFi produced large improvements in clinical response at 12 weeks, with 37% achieving ACR50 compared to 8% with placebo (RR 5.63, 95% CI 3.98 to 7.96). An earlier meta-analysis found that more patients achieved ACR20, ACR50, and PsARC responses with anti-TNF agents compared to controls at 24 weeks, with etanercept and infliximab showing higher ACR70 response rates. Physical function improved with TNFi treatment at 24 weeks.
Efficacy in Psoriasis
TNF inhibitors demonstrated high efficacy for moderate-to-severe plaque psoriasis. Infliximab showed the highest probability of PASI 75 achievement at 81%, followed by adalimumab at 71% and etanercept at 50%. The Chaudhari trial of infliximab found 82% achieved good ratings on Physician’s Global Assessment at week 10 versus 18% with placebo.
Safety Profile
The safety profile of TNF inhibitors appeared favorable. At trial end, 4% of TNFi-treated patients experienced serious adverse events versus 3% with placebo. However, TNFi slightly increased withdrawals due to adverse events: 3% with TNFi versus 2% with placebo.
Paradoxical Psoriasis During TNF Inhibitor Therapy
Paradoxical new-onset or worsening psoriasis emerged as a recognized adverse event in patients receiving these agents for other indications. The incidence rate varied significantly by agent: adalimumab showed a 4.6-fold higher rate than etanercept and 3.5-fold higher than infliximab. Among patients, clinical presentations included various forms of psoriasis, with 66% continuing therapy successfully with concurrent psoriasis treatments.
Synthesis
The evidence reveals an apparent paradox: TNF inhibitors demonstrate substantial efficacy in treating both psoriatic arthritis and moderate-to-severe psoriasis, yet simultaneously induce or exacerbate psoriasis in patients. While TNF-α plays a pivotal role in established psoriasis pathogenesis, its inhibition may trigger compensatory pathways that precipitate psoriatic lesions in genetically predisposed individuals. The decision to continue or switch therapy depends on balancing control of the primary indication against the severity of induced psoriasis.